



Final Appraisal Recommendation

Advice No: 0118 – February 2018

Rolapitant (Varuby®) 90 mg film-coated tablet

Submission by TESARO UK Ltd

Recommendation of AWMSG

Rolapitant (Varuby®) is not recommended for use within NHS Wales for the prevention of delayed nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults.

The case for cost-effectiveness has not been proven.

Additional note(s):

- Patients who are currently being treated with rolapitant (Varuby®) for the indication stated above should have the option to continue their therapy until they and their clinicians consider it appropriate to stop.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 1303), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group Final Appraisal Recommendation – 0118:
Rolapitant (Varuby®) 90 mg film-coated tablet. February 2018.